Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer

Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer

Abstract Background The pancreatic cancer vaccine, GVAX, induces novel lymphoid aggregates in the otherwise immune quiescent pancreatic ductal adenocarcinoma (PDAC). GVAX also upregulates the PD-1/PD-L1 pathway, and a pre-clinical model demonstrated the anti-tumor effects of combination GVAX and ant...

Full description

Bibliographic Details
Main Authors: May Tun Saung, Stephen Muth, Ding Ding, Dwayne L. Thomas, Alex B. Blair, Takahiro Tsujikawa, Lisa Coussens, Elizabeth M. Jaffee, Lei Zheng
Format: Article
Language:English
Published: BMJ Publishing Group 2018-11-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Pancreatic ductal adenocarcinoma
Lymphoid aggregates
Cytotoxic T-cells
Tumor associated macrophages
Dendritic cells
PD-1
Online Access:http://link.springer.com/article/10.1186/s40425-018-0435-6

Internet

http://link.springer.com/article/10.1186/s40425-018-0435-6

Similar Items